Eric Warren : Yes, Jason, as so they’re now aligned with our label there in ASCVD patients they’re on a documented maximally tolerated statin dose and they’re not at their LDL-C goal. So that is a typical approvable patient. Now I will say that there is a strong desire to prescribe us in a patient that has for a primary prevention. So they don’t have active ASCVD, but they have risk factors. There’s also a strong desire to prescribers and patients that are unable or unwilling to take statins. So, both of those will go away with the new label as we add in the primary prevention and as we remove that dependency on maximally tolerated statins.
Jason Zemansky : Great. Thanks guys.
Eric Warren : Great. Thanks a lot Jason.
Operator: Thank you. One moment for our next question, please. Our next question comes from the line of Serge Belanger with Needham. Your line is now open.
Serge Belanger: Hi, good morning. A couple of questions. On the rule 12(c) motion. So you mentioned the trial date in mid-April is still on the calendar, does that remain on the calendar until there is a decision on this motion. And then in terms of the appeals process here, is it the same with the 12(c) motion as it would be if it went to a truck? Then I have a couple of follow-ups.
Sheldon Koenig: First of all, thank you Serge, and glad you could make the call. As it relates to the trial date of April 15 that will remain on the calendar as a matter of fact should the ruling that once a motion is reviewed and if there is no decision, then it no harm no foul. We remain on the same schedule, which is the April 13 trial date. And then your second was as it relates to appeals, as it relates to the appeal process, there is certainly the ability to appeal. Obviously, we’ve done some research in this area and we just have to take it day by day as it relates two what would happen in the case of an appeal.
Serge Belanger: Okay. And then on the business front maybe just update us on your prior outlook rate and whether you expect any additional formulary coverage ahead of March 31?
JoAnne Foody: So we’ve had the opportunity to get to almost 90% of the payers with the CVOT data. I’m pleased to say Sheldon had outlined as well not only have we had new formulary access with very large payers as well as small regional payers, but also the UM criteria has been aligning with the CVOT data already. With that our approval rates have also been quite well since that those presentations and since the CVOT data as well. So I can tell you that we’re up to approval rates that are very much almost to the 85% range in commercial and equal to that in Medicare.
Serge Belanger: Thank you.
Sheldon Koenig: And sorry just one other note, I was thinking it might be easier to answer that question regarding your question about 12(c) motions and appeals. As I mentioned, we would have to see how it goes. But I think you would agree with me that if we win that motion. That’s a big way. So we can worry about appeal as it comes. But it’ll be a nice it’s a nice indicator. It’s a yes essentially the case that we have there.
Operator: And thank you. I would now like to turn the conference back to Mr. Sheldon Koenig President and Chief Executive Officer. For closing remarks.
